Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.

摘要: BACKGROUND Paclitaxel (Taxol), a diterpene plant product that promotes tubulin polymerization, has documented activity against number of solid tumors, including ovarian cancer and breast cancer. PURPOSE Our purpose was to conduct phase II clinical trial investigating the response patients with advanced recurrent carcinoma high-dose paclitaxel combined granulocyte colony-stimulating factor (G-CSF). METHODS A prospective advanced-stage, undertaken. Patients received 250 mg/m2 every 21 days; cycles were given on rigid schedule; delays permitted only for extreme circumstances. G-CSF at dose 10 micrograms/kg per day ameliorate myelo-suppression. If patient showed fever neutropenia, dosage increased 20 so intensity could be maintained. assessed two cycles, those complete radiographic resolution disease underwent peritoneoscopy. RESULTS Forty-four assessable response. Twenty-one had reduction in tumor volume greater than 50%, yielding an objective rate 48% (21 44 patients; 95% confidence interval, 32%-63%). Six (14%) disease; six also negative biopsy specimens washings Age, prior regimens, platinum resistance did not influence or ability maintain intensity. Dose maintained targeted level up 14 consecutive therapy. CONCLUSIONS We observed dose-intense platinum-resistant, The is higher previously reported lower similar cohorts treated without G-CSF. Comparison studies suggests dose-response relationship. Therapy should considered advanced, platinum-refractory